Medcura

About Medcura

Medcura Inc. operates as a commercial-stage medical device company focused on developing and commercializing a portfolio of hemostatic and wound treatment products. The company was founded by Matthew Dowling, PhD, who now serves as the Chief Scientific Officer, and is led by Executive Chairman Larry Tiffany and CEO Jim Buck. Larry Tiffany is a serial entrepreneur who previously founded and sold the neuro-molecular testing company DioGenix. His experience includes raising venture capital and holding senior management positions at various pharmaceutical and genomics companies. Jim Buck brings over 30 years of experience in commercializing medical technologies, including a key role at Closure Medical, which was acquired by Johnson & Johnson.

The company's business model revolves around leveraging its proprietary technology platform to create cost-effective solutions for bleeding management across surgical, medical, and consumer markets. This platform utilizes hydrophobically modified natural biomaterials, such as chitosan, to mechanically adhere to bleeding sites without causing swelling, a significant differentiator from many existing hemostatic agents. Medcura generates revenue through the sale of its products, which are available in major retail stores like CVS and on Amazon, and by developing high-value applications for the surgical and military sectors. The company serves surgeons, healthcare providers, the military, and consumers.

Medcura's product pipeline includes Rapid-Seal®, an antibacterial first-aid product, and two key products under development that have received FDA Breakthrough Device Designation. LifeFoam™ is an injectable biopolymer foam designed to treat severe internal bleeding from traumatic injuries, a major focus for military applications. LifeGel™ is an absorbable, no-swell surgical hemostatic gel developed for procedures where swelling is a major concern, such as spinal surgery. Unlike competitors, LifeGel™ is ready-to-use, requires no special storage, and is designed to be absorbed by the body within weeks, reducing the risk of complications like nerve damage. The company has secured substantial funding, raising a total of $87.3 million over six rounds to support product development and commercial expansion.